Company Filing History:
2 out of 330 
2 out of 74 
1 out of 2 Years Active: 2009-2011
Title: **Stephen Cobbold: Innovator in Primate Immunology**
Introduction
Stephen Cobbold, based in Witney, GB, is a notable inventor recognized for his contributions to immunology through his innovative patents. With a focus on inducing tolerance in primates, his work holds promise for advancements in medical treatments and therapies.
Latest Patents
Cobbold holds two significant patents that highlight his expertise in the field. The first patent, titled "Compositions and methods of tolerizing a primate to an antigen," describes a method of inducing tolerance in a primate using a compound or a combination of compounds that exhibit specific characteristics when tested in vitro. A pivotal component of this patent is the TRX1 antibody, utilized in conjunction with a defined dosing regimen to achieve desirable outcomes. The second patent, "Anti-CD4 antibodies," follows a similar theme, emphasizing the induction of tolerance in primates through targeted compounds, notably the TRX1 antibody, again in line with a specified dosing regimen.
Career Highlights
Cobbold has made impactful strides in his career, working with notable organizations such as Isis Innovation Limited and Cambridge University Technical Services Limited. His contributions in these roles have helped bridge the gap between academic research and practical applications, facilitating the development of pioneering therapeutic methods.
Collaborations
Throughout his journey, Stephen Cobbold has collaborated with esteemed colleagues including Mark Raymond Frewin and Herman Waldmann. These partnerships have fostered a collaborative environment that drives innovation and enhances the research outcomes in immunology.
Conclusion
Stephen Cobbold's inventive spirit and dedication to advancing medical science through his patents underscore the importance of innovation in healthcare. His work not only illustrates his commitment to research but also paves the way for future advancements in antibody therapies aimed at improving tolerance in primate subjects.